GlassScriptPhysician profile
David J Ellis
NPI 1306896279
$43,650.06
in general payments reported to CMS, 2019-2025
59 companies · $11K in 2025
The $11K reported for 2025 was more than what 94% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $2,019 · 2021: $3,870 · 2022: $1,461 · 2023: $3,825 · 2024: $9,935 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,820 · Food and Beverage: $8,090 · Honoraria: $4,125 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,187 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,820.00 |
| Food and Beverage | $8,089.54 |
| Honoraria | $4,125.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,187.44 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $6,298.72 | 2019-2025 | |
| Astellas Pharma US INC | $5,006.27 | 2019-2025 | Padcev, Xtandi, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $4,829.37 | 2019-2025 | |
| Integra Gpo, LLC | $4,803.07 | 2019 | |
| Urogen Pharma, INC. | $4,476.47 | 2020-2025 | Jelmyto |
| Janssen Biotech, INC. | $2,835.36 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Clovis Oncology, INC. | $2,368.09 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $1,690.54 | 2019-2025 | Adstiladrin |
| Dendreon Pharmaceuticals LLC | $1,638.66 | 2019-2025 | Provenge |
| Verity Pharmaceuticals INC. | $1,270.29 | 2021-2025 | Trelstar |
| Telix Pharmaceuticals | $1,210.23 | 2023-2025 | Illuccix |
| E.R. Squibb & Sons, L.L.C. | $850.00 | 2021 | |
| Accord Healthcare, INC. | $806.64 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $507.54 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $366.15 | 2020-2025 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.